CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG

Bone

Volumn 73, Issue , 2015, Pages 242-248

  Aoyama, Eriko ^a   Kubota, Satoshi ^a,b   Khattab, Hany Mohamed ^a   Nishida, Takashi ^b   Takigawa, Masaharu ^a,b  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

CCN2 family protein 2 (CCN2); Osteoclast; Osteoprotegerin (OPG); RANK ligand (RANKL); Receptor activator of nuclear factor B ligand (RANK)

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; CTGF PROTEIN, MOUSE; TNFRSF11A PROTEIN, MOUSE; TNFRSF11B PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; MALE; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; METABOLISM; OSTEOCLAST; PHYSIOLOGY;

ANIMALS; CELL DIFFERENTIATION; CELL LINE; CONNECTIVE TISSUE GROWTH FACTOR; MICE; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SURFACE PLASMON RESONANCE;

EID: 84922523169     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.12.058     Document Type: Article

References (46)

1. Perbal B., Takigawa M. CCN proteins: a new family of cell growth and differentiation regulators 2005, 1-311. Imperial College Press, London, UK. B. Perbal, M. Takigawa (Eds.).
2. Takigawa M., Nakanishi T., Kubota S., Nishida T. Role of CTGF/HCS24/ecogenin in skeletal growth control. J Cell Physiol 2003, 194(3):256-266.
3. Kubota S., Takigawa M. Role of CCN2/CTGF/Hcs24 in bone growth. Int Rev Cytol 2007, 257:1-41.
4. Takigawa M. CCN2: a master regulator of the genesis of bone and cartilage. J Cell Commun Signal 2013, 7(3):191-201.
5. Nishida T., Emura K., Kubota S., Lyons K.M., Takigawa M. CCN family 2/connective tissue growth factor (CCN2/CTGF) promotes osteoclastogenesis via induction of and interaction with dendritic cell-specific transmembrane protein (DC-STAMP). J Bone Miner Res 2011, 26(2):351-363.
6. Ivkovic S., Yoon B.S., Popoff S.N., Safadi F.F., Libuda D.E., Stephenson R.C., et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003, 130(12):2779-2791.
7. Tomita N., Hattori T., Itoh S., Aoyama E., Yao M., Yamashiro T., et al. Cartilage-specific over-expression of CCN family member 2/connective tissue growth factor (CCN2/CTGF) stimulates insulin-like growth factor expression and bone growth. PLoS One 2013, 8(3):e59226.
8. Nishida T., Kubota S., Aoyama E., Janune D., Maeda A., Takigawa M. Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes. Endocrinology 2011, 152(11):4232-4241.
9. Abd El Kader T., Kubota S., Nishida T., Hattori T., Aoyama E., Janune D., et al. The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo. Bone 2014, 59:180-188.
10. Maeda A., Nishida T., Aoyama E., Kubota S., Lyons K.M., Kuboki T., et al. CCN family 2/connective tissue growth factor modulates BMP signalling as a signal conductor, which action regulates the proliferation and differentiation of chondrocytes. J Biochem 2009, 145(2):207-216.
11. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4(8):599-604.
12. Aoyama E., Kubota S., Takigawa M. CCN2/CTGF binds to fibroblast growth factor receptor 2 and modulates its signaling. FEBS Lett 2012, 586(24):4270-4275.
13. Wahab N.A., Weston B.S., Mason R.M. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 2005, 16(2):340-351.
14. Kawata K., Kubota S., Eguchi T., Aoyama E., Moritani N.H., Kondo S., et al. Role of LRP1 in transport of CCN2 protein in chondrocytes. J Cell Sci 2012, 125(Pt 12):2965-2972.
15. Segarini P.R., Nesbitt J.E., Li D., Hays L.G., Yates J.R., Carmichael D.F. The low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor is a receptor for connective tissue growth factor. J Biol Chem 2001, 276(44):40659-40667.
16. Ball D.K., Rachfal A.W., Kemper S.A., Brigstock D.R. The heparin-binding 10kDa fragment of connective tissue growth factor (CTGF) containing module 4 alone stimulates cell adhesion. J Endocrinol 2003, 176(2):R1-R7.
17. Aoyama E., Hattori T., Hoshijima M., Araki D., Nishida T., Kubota S., et al. N-terminal domains of CCN family 2/connective tissue growth factor bind to aggrecan. Biochem J 2009, 420(3):413-420.
18. Hoshijima M., Hattori T., Aoyama E., Nishida T., Yamashiro T., Takigawa M. Roles of heterotypic CCN2/CTGF-CCN3/NOV and homotypic CCN2-CCN2 interactions in expression of the differentiated phenotype of chondrocytes. FEBS J 2012, 279(19):3584-3597.
19. Kawasaki M., Fujishiro M., Yamaguchi A., Nozawa K., Kaneko H., Takasaki Y., et al. Possible role of the JAK/STAT pathways in the regulation of T cell-interferon related genes in systemic lupus erythematosus. Lupus 2011, 20(12):1231-1239.
20. Leibbrandt A., Penninger J.M. RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci 2008, 1143:123-150.
21. Wright H.L., McCarthy H.S., Middleton J., Marshall M.J. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009, 2(1):56-64.
22. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999, 96(7):3540-3545.
23. Shimo T., Kubota S., Goda T., Yoshihama Y., Kurio N., Nishida T., et al. Clinical significance and pathogenic function of connective tissue growth factor (CTGF/CCN2) in osteolytic mandibular squamous cell carcinoma. Anticancer Res 2008, 28(4C):2343-2348.
24. Nozawa K., Fujishiro M., Kawasaki M., Kaneko H., Iwabuchi K., Yanagida M., et al. Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis. Arthritis Res Ther 2009, 11(6):R174.
25. Shimo T., Kubota S., Yoshioka N., Ibaragi S., Isowa S., Eguchi T., et al. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 2006, 21(7):1045-1059.
26. Kawaki H., Kubota S., Aoyama E., Fujita N., Hanagata H., Miyauchi A., et al. Design and utility of CCN2 anchor peptide aptamers. Biochimie 2010, 92(8):1010-1015.
27. Takayanagi H., Kim S., Koga T., Nishina H., Isshiki M., Yoshida H., et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002, 3(6):889-901.
28. Darnay B.G., Haridas V., Ni J., Moore P.A., Aggarwal B.B. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappaB and c-Jun N-terminal kinase. J Biol Chem 1998, 273(32):20551-20555.
29. Liu C., Walter T.S., Huang P., Zhang S., Zhu X., Wu Y., et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 2010, 184(12):6910-6919.
30. Zhang S., Liu C., Huang P., Zhou S., Ren J., Kitamura Y., et al. The affinity of human RANK binding to its ligand RANKL. Arch Biochem Biophys 2009, 487(1):49-53.
31. Boyle W.J., Simonet W.S., Lacey D.L. Osteoclast differentiation and activation. Nature 2003, 423(6937):337-342.
32. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93(2):165-176.
33. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Mochizuki S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95(7):3597-3602.
34. Vitovski S., Phillips J.S., Sayers J., Croucher P.I. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 2007, 282(43):31601-31609.
35. Velasco C.R., Baud'huin M., Sinquin C., Maillasson M., Heymann D., Colliec-Jouault S., et al. Effects of a sulfated exopolysaccharide produced by Altermonas infernus on bone biology. Glycobiology 2011, 21(6):781-795.
36. Naidu V.G., Dinesh Babu K.R., Thwin M.M., Satish R.L., Kumar P.V., Gopalakrishnakone P. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-kappaB activation and down regulating inflammatory cytokines. Chem Biol Interact 2013, 203(2):467-479.
37. Xing L., Bushnell T.P., Carlson L., Tai Z., Tondravi M., Siebenlist U., et al. NF-kappaB p50 and p52 expression is not required for RANK-expressing osteoclast progenitor formation but is essential for RANK- and cytokine-mediated osteoclastogenesis. J Bone Miner Res 2002, 17(7):1200-1210.
38. Franzoso G., Carlson L., Xing L., Poljak L., Shores E.W., Brown K.D., et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997, 11(24):3482-3496.
39. Matsumoto M., Sudo T., Saito T., Osada H., Tsujimoto M. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000, 275(40):31155-31161.
40. Matsumoto M., Kogawa M., Wada S., Takayanagi H., Tsujimoto M., Katayama S., et al. Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1. J Biol Chem 2004, 279(44):45969-45979.
41. Wagner E.F., Matsuo K. Signalling in osteoclasts and the role of Fos/AP1 proteins. Ann Rheum Dis 2003, 62(Suppl. 2):ii83-ii85.
42. Hotokezaka H., Sakai E., Kanaoka K., Saito K., Matsuo K., Kitaura H., et al. U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002, 277(49):47366-47372.
43. Grigoriadis A.E., Wang Z.Q., Cecchini M.G., Hofstetter W., Felix R., Fleisch H.A., et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994, 266(5184):443-448.
44. Matsuo K., Galson D.L., Zhao C., Peng L., Laplace C., Wang K.Z., et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004, 279(25):26475-26480.
45. Kanazawa K., Kudo A. Self-assembled RANK induces osteoclastogenesis ligand-independently. J Bone Miner Res 2005, 20(11):2053-2060.
46. Hakozaki A., Yoda M., Tohmonda T., Furukawa M., Hikata T., Uchikawa S., et al. Receptor activator of NF-kappaB (RANK) ligand induces ectodomain shedding of RANK in murine RAW264.7 macrophages. J Immunol 2010, 184(5):2442-2448.